Here we extend the platform to targets of interest in cardiovascular disease, including PCSK9, ANGPLT3 and ApoC3. METHODS: Chemically modified siRNAs were designed and were screened for potency in ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

As it prepares to present the latest data from the phase I/II clinical trial of EO-2463, Enterome SA has secured $19 million to expand and complete the study, and to scope phase III development of the ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

Potential treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases may already be out there in ...

Merck (MRK) stock was on the move Monday after the healthcare company announced positive results from two Phase 3 clinical trials. These studies saw meaningful reductions in LDL-C from patients with ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...